Crestor Pipeline and Next-Gen: Rosuvastatin Regulatory History, Label Updates, and What Comes Next

What the 2003 approval covered

Crestor was approved on August 12, 2003, as a Type 1 new molecular entity under standard review, for 5, 10, 20 and 40 mg tablets under NDA 021366 [2]. Rosuvastatin is an HMG-CoA reductase inhibitor and, unlike simvastatin, is not a prodrug; more than 90% of active plasma activity comes from the parent compound [1]. Generic rosuvastatin is widely available [1][2].

Current indications and dosing

The current label, effective September 23, 2026, lists cardiovascular risk reduction in adults at increased risk, LDL-C lowering in adults with primary hypercholesterolemia, slowing of atherosclerosis in adults, HeFH in adults and children 8 and older, HoFH in adults and children 7 and older, primary dysbetalipoproteinemia, and hypertriglyceridemia [1]. The label recommends an adult dosage range of 5 to 40 mg once daily, taken at any time of day with or without food, with LDL-C assessed as early as 4 weeks after starting [1]. It recommends starting Asian patients at 5 mg daily, and for patients with severe renal impairment who are not on hemodialysis, starting Crestor at 5 mg once daily and not exceeding 10 mg once daily [1].

Label changes that matter for safety

The current label has no boxed warning [1]. Myopathy and rhabdomyolysis risk is higher at 40 mg and with age 65 or older, uncontrolled hypothyroidism, renal impairment and certain interacting drugs; the label says Asian patients may be at higher risk [1]. In pooled placebo-controlled trials, transaminases above 3 times the upper limit of normal occurred in 1.1% on Crestor versus 0.5% on placebo [1]. Proteinuria and hematuria were more frequent on 40 mg and generally transient; the label says to consider dose reduction for unexplained persistent proteinuria or hematuria [1]. Pregnancy is not a contraindication; the label says to discontinue when pregnancy is recognized or consider ongoing therapeutic needs, and breastfeeding is not recommended [1]. The contraindications are acute liver failure or decompensated cirrhosis and hypersensitivity [1]. Cyclosporine and gemfibrozil are not contraindications; the label limits Crestor to 5 mg daily with cyclosporine, and recommends avoiding gemfibrozil or, if unavoidable, starting at 5 mg and limiting the dose to 10 mg daily [1].

What the JUPITER data show

JUPITER enrolled 17,802 apparently healthy men aged 50 and older and women aged 60 and older with LDL-C under 130 mg/dL and hsCRP 2.0 mg/L or higher [3]. Rosuvastatin 20 mg reduced LDL-C by 50% and hsCRP by 37%; the primary endpoint rate was 0.77 versus 1.36 per 100 person-years, hazard ratio 0.56, 95% CI 0.46 to 0.69, and the trial stopped at a median of 1.9 years [3]. The label gives 142 versus 252 events, a 44% relative risk reduction and a 1.2% absolute risk reduction [1].

Recent label revisions

The NDA 021366 approval history lists labeling supplements through September 23, 2026 [2]. The current label's recent major changes are Indications and Usage in 04/2026 and dosage modifications due to drug interactions in 09/2026 [1].